Thanks for the heads up on NWCI.OB
The party's just starting here. Once you read through the amazing resumes of the BODs and the officers, you get to the meat and potatoes:
From the website:
Building on positive industry attention to cardiac safety and our increasingly robust clinical validation, we officially launched QTinno in August. QTinno provides an automated analysis of cardiac safety in drug development. This launch was enabled by an extensive effort by us to ensure organizational readiness to effectively support the sale, implementation and support of QTinno. As many of our shareholders know, every drug in development must undergo a TQT study to determine cardiac toxicity, and currently these studies involve manual or semi-automated readings by cardiologists.. We believe QTinno will replace this primarily manual process with a fully automated solution which promises higher quality results and a more efficient approach.
With our lead product launched, we continue to make steady progress toward securing revenue-generating studies. Notable commercialization-related achievements include:
* A top-five pharmaceutical company named QTinno as the technology that will be used in all of its fully automated TQT studies. This pharmaceutical company evaluated several automated cardiac safety solutions before choosing QTinno.
* A Master Services Agreement (MSA) was signed with a top-three Clinical Research Organization (CRO), which will use QTinno as their technology in fully automated Phase I TQT studies delivered by their centralized ECG core lab. We expect to collaborate on the first fully automated study in the near future and anticipate the customer will increasingly deliver fully automated studies with QTinno.
* Another top-five CRO also signed an MSA with us, licensing QTinno in all TQT studies where fully automated readings are obtained. QTinno will enable them to eliminate the need to utilize ECG core labs for TQT studies delivered by their Phase I units. Ultimately, QTinno will provide the CRO with incremental revenue opportunities by capturing fees that were previously outsourced to ECG core labs.
* Dedicated Phase I, an innovative provider of clinical research services signed an MSA with us, licensing our QTinno software solution in all TQT studies where fully automated readings are obtained.
With Qtinno, the company has pulled the ladder up behind them IMO. They have stormed the market with the new benchmark for monitoring cardiac safety, which all companies proposing new drugs will need to utilize. The low float is the added sweetener here. It's easy to see why the company is a likely candidate for a buyout, and why, even after the nice run-up in the PPS, today's closing price is just the beginning.
AI
